Back to top
more

Constellation Pharmaceuticals, Inc. (CNST)

(Delayed Data from NSDQ)

$13.30 USD

13.30
20,840

+0.45 (3.50%)

Updated May 3, 2019 04:00 PM ET

After-Market: $13.15 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Constellation (CNST) Surges on Takeover Deal With MorphoSys

by Zacks Equity Research

Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.

Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season?

by Zacks Equity Research

Constellation Pharmaceuticals (CNST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is Constellation (CNST) Stock a Solid Choice Right Now?

by Zacks Equity Research

Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock

by Zacks Equity Research

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why You Shouldn't Bet Against Constellation Pharmaceuticals (CNST) Stock

by Zacks Equity Research

Constellation Pharmaceuticals (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock

by Zacks Equity Research

Constellation Pharmaceuticals, Inc. (CNST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

Biotech Rally Sends Nasdaq to 9000: ETFs in Focus

by Sanghamitra Saha

Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

by Sweta Killa

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Here's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST)

by Zacks Equity Research

Does Constellation Pharmaceuticals, Inc. (CNST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Will Constellation Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Constellation Pharmaceuticals.

Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session

by Zacks Equity Research

Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

What's in Store for Universal Health (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.

Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter earnings trump estimates on the back of lower costs and higher premium revenues.

Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y

by Zacks Equity Research

Ensign Group's (ENSG) fourth-quarter earnings rise on the back of solid segmental growth.

MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y

by Zacks Equity Research

Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.

Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings?

by Zacks Equity Research

For the fourth quarter, T-Mobile (TMUS) is likely to report higher year-over-year revenues driven by customer growth on the back of coverage expansion and network performance.

Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings?

by Zacks Equity Research

For the fourth quarter, GoPro (GPRO) is likely to report higher year-over-year revenues driven by increasing market traction of HERO7 Black.